Segment Evaluation and Major Growth Areas in the Spray-Dried Biologics Market

The spray-dried biologics market is poised for significant expansion in the coming years, driven by technological advancements and growing demand for innovative drug delivery methods. As pharmaceutical companies and researchers focus on improving biologic stability and patient convenience, this sector is expected to experience robust growth and evolving opportunities through 2030.

Market Size and Growth Expectations for the Spray-Dried Biologics Market
The spray-dried biologics market is projected to grow rapidly, reaching a value of $3.2 billion by 2030. This growth is forecasted at a compound annual growth rate (CAGR) of 11.4%. Key factors contributing to this expansion include a rising preference for non-injectable biologic therapies, increased investments in dry powder delivery systems, and the worldwide expansion of vaccine manufacturing capacity. Innovations aimed at reducing cold-chain requirements and advancements in spray-drying equipment designs also play significant roles. Important trends shaping the market in the forecast period are the wider use of spray-drying techniques to enhance biologic stability, growing demand for inhalable and oral biologic products, continuous spray-drying processes, increased application of dry powder biologics in vaccines, and a stronger emphasis on prolonging product shelf life.

Download a free sample of the spray-dried biologics market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30401&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Spray-Dried Biologics Industry
Several prominent players dominate the spray-dried biologics market, including Thermo Fisher Scientific Inc., Evonik Industries AG, Lonza Group AG, GEA Group, Fareva Group, Almac Group Limited, Seqens Group, Fabbrica Italiana Sintetici S.p.A., CordenPharma International, Hovione FarmaCiencia SA, Veranova Inc., Pace Analytical Services LLC, Olon S.p.A., Nova Laboratories Ltd, Leukocare AG, Micro Sphere SA, Seran Bioscience LLC, CritiTech Particle Engineering Solutions LLC, Xedev BV, and BÜCHI Labortechnik AG.

Strategic Collaborations Enhancing Capabilities in Spray-Dried Biologics
In May 2023, Hovione, a Portugal-based CDMO specializing in spray drying and particle engineering, formed a partnership with H&T Presspart to advance device technology for delivering dry powder inhalation formulations. This collaboration focuses on integrating Presspart's Sunriser capsule-based dry powder inhaler platform with Hovione's formulation expertise to improve the efficiency and commercial viability of inhalation therapies. H&T Presspart, headquartered in Germany, is known for manufacturing drug delivery devices and components, specifically inhalation technologies.

View the full spray-dried biologics market report:
https://www.thebusinessresearchcompany.com/report/global-spray-dried-biologics-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Technological Advancements Creating Market Opportunities in Spray-Dried Biologics
Industry leaders are increasingly adopting cutting-edge technologies such as drum dosing to improve dosing accuracy, powder handling, and scalability in capsule filling processes. Drum dosing utilizes a rotating drum equipped with precision dosing cavities and vacuum transfer to accurately fill capsules with dry powders, enabling consistent low-dose filling and better flow control of spray-dried materials. For example, in February 2024, Catalent Inc., a US-based CDMO, enhanced its inhalation manufacturing site by incorporating drum-based dosing systems combined with in-line mass verification technology. This upgrade supports precise filling of engineered spray-dried powders with real-time dose validation and controlled low-humidity conditions, boosting production efficiency and product consistency for commercial-scale dry powder inhalation biologics.

Market Segmentation Highlighting the Spray-Dried Biologics Industry's Structure
The report segments the spray-dried biologics market into the following categories:
1) Product Type: Monoclonal Antibodies, Vaccines, Enzymes, Hormones, and Other Product Types
2) Route of Administration: Oral, Inhalation or Pulmonary, Injectable, Topical
3) End-User: Hospitals, Research Institutes, Pharmaceutical and Biotechnology Companies, and Other End-Users

Further breakdowns include:
- Monoclonal Antibodies: Chimeric, Humanized, Fully Human, Bispecific, and Antibody Fragments
- Vaccines: Live Attenuated, Inactivated, Subunit, Toxoid, Viral Vector, and Recombinant Protein Vaccines
- Enzymes: Therapeutic, Digestive, Metabolic, Recombinant, and Replacement Enzymes
- Hormones: Peptide, Protein, Steroid, Recombinant, and Growth Hormones
- Other Products: Blood Factors, Cytokines, Fusion Proteins, Nucleic Acid Therapeutics, and Cell Culture Media Proteins

This detailed segmentation offers a comprehensive view of the various biologic types, administration routes, and end users shaping the spray-dried biologics market landscape.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.